- Home
- VGI vs GNLX Comparison
VGI vs GNLX Comparison
Compare VGI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | GNLX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 110.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | VGI | GNLX |
|---|---|---|
| Price | $6.78 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 40.4K | ★ 266.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.74 | $2.29 |
| 52 Week High | $8.04 | $8.54 |
Technical Indicators
Market Signals| Indicator | VGI | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 19.12 | 44.65 |
| Support Level | N/A | $2.34 |
| Resistance Level | $7.59 | $2.86 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 17.65 | 39.29 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.